Our COVID-19 vaccine pill may help overcome many of the most important challenges posed by the global COVID-19 pandemic – and achieve high rates of vaccination.
By priming the immune system with a broader mucosal response than mRNA vaccines, it may also deliver greater protection.
Our trials show that in animals our vaccine candidate inhibited transmission. And trials with people suggest that the vaccine we are developing could thwart variants of the original virus.
Because it may be more durable, our vaccine could alleviate much of the pressure on public health authorities to provide boosters against new variants.
And since our vaccines will come in the form of pills swallowed with a glass of water, we also avoid the public’s common resistance to needles and injections.
More people vaccinated with less public anxiety and fewer hurdles – that is the promise that a Vaxart COVID-19 pill holds out.
